Anticancer iridium(iii) cyclopentadienyl complexes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F25%3A73633963" target="_blank" >RIV/61989592:15310/25:73633963 - isvavai.cz</a>

Výsledek na webu

<a href="https://pubs.rsc.org/en/content/articlelanding/2025/qi/d4qi02472a" target="_blank" >https://pubs.rsc.org/en/content/articlelanding/2025/qi/d4qi02472a</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1039/d4qi02472a" target="_blank" >10.1039/d4qi02472a</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Anticancer iridium(iii) cyclopentadienyl complexes

Popis výsledku v původním jazyce

Platinum-based anticancer drugs have been highly effective at treating various cancers. While they have shown significant promise, their potential limitations have motivated researchers to explore other noble metal-based compounds, including iridium (Ir) complexes. Among these, half-sandwich Ir(iii) cyclopentadienyl (Ir-Cpx) complexes have emerged as promising new anticancer compounds. This relatively new area of bioinorganic chemistry has made significant progress since its inception in 2007, although no representative has yet entered clinical trials. Recent studies over the past 5-10 years have significantly advanced our understanding of the stability, speciation, intracellular localization, target organelles and molecular targets involved in the mechanisms of action (MoAs) of these compounds. This comprehensive review provides the reader with an overview of anticancer Ir-Cpx complexes and diverse chemical, biochemical and biological methods used for their research and development. Structure-activity relationships (SARs) and mechanisms of action (MoAs) are discussed with respect to anticancer activity and in comparison with their structurally similar ruthenium(ii), rhodium(iii) and osmium(ii) analogues. Considerable attention is paid to in vivo anticancer activity and related aspects, such as drug delivery strategies, multi-component drugs or photodynamic therapy.

Název v anglickém jazyce

Anticancer iridium(iii) cyclopentadienyl complexes

Popis výsledku anglicky

Platinum-based anticancer drugs have been highly effective at treating various cancers. While they have shown significant promise, their potential limitations have motivated researchers to explore other noble metal-based compounds, including iridium (Ir) complexes. Among these, half-sandwich Ir(iii) cyclopentadienyl (Ir-Cpx) complexes have emerged as promising new anticancer compounds. This relatively new area of bioinorganic chemistry has made significant progress since its inception in 2007, although no representative has yet entered clinical trials. Recent studies over the past 5-10 years have significantly advanced our understanding of the stability, speciation, intracellular localization, target organelles and molecular targets involved in the mechanisms of action (MoAs) of these compounds. This comprehensive review provides the reader with an overview of anticancer Ir-Cpx complexes and diverse chemical, biochemical and biological methods used for their research and development. Structure-activity relationships (SARs) and mechanisms of action (MoAs) are discussed with respect to anticancer activity and in comparison with their structurally similar ruthenium(ii), rhodium(iii) and osmium(ii) analogues. Considerable attention is paid to in vivo anticancer activity and related aspects, such as drug delivery strategies, multi-component drugs or photodynamic therapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10402 - Inorganic and nuclear chemistry

Projekt

<a href="/cs/project/NU22-08-00236" target="_blank" >NU22-08-00236: Preklinické studie neplatinových metaloléčiv v terapii rakoviny plic</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Inorganic Chemistry Frontiers

ISSN

2052-1545

e-ISSN

2052-1553

Svazek periodika

12

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

58

Strana od-do

897-954

Kód UT WoS článku

001386345400001

EID výsledku v databázi Scopus

2-s2.0-85213039373